SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice
Heterozygous mutation targeting proline 95 in Serine/Arginine-rich Splicing Factor 2 (SRSF2) is associated with V617F mutation in Janus Activated Kinase 2 (JAK2) in some myeloproliferative neoplasms (MPNs), most commonly primary myelofibrosis. To explore the interaction of Srsf2P95H with Jak2V617F,...
Main Authors: | Willekens, C, Laplane, L, Dagher, T, Benlabiod, C, Papadopoulos, N, Lacout, C, Rameau, P, Catelain, C, Alfaro, A, Edmond, V, Signolle, N, Marchand, V, Droin, N, Hoogenboezem, R, Schneider, RK, Penson, A, Abdel-Wahab, O, Giraudier, S, Pasquier, F, Marty, C, Plo, I, Villeval, J-L, Constantinescu, SN, Porteu, F, Vainchenker, W, Solary, E |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Springer Nature
2023
|
Similar Items
-
Recent advances in therapies for primary myelofibrosis
by: Vainchenker, W, et al.
Published: (2023) -
Guideline for the diagnosis and management of myelofibrosis
by: Reilly, J, et al.
Published: (2012) -
Guideline for the diagnosis and management of myelofibrosis.
by: Reilly, J, et al.
Published: (2012) -
Exploring the role of the RNA-binding protein SRSF3 in the developing heart
by: Lupu, IE
Published: (2019) -
Practical management of patients with myelofibrosis receiving ruxolitinib.
by: Harrison, C, et al.
Published: (2013)